Coston McIsaac & Partners’s AstraZeneca AZN Stock Holding History

Coston McIsaac & Partners’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2K	Hold	15	–	–	﹤0.01%	758
2026 Q1	$2K	Sell	15 -1	-6%	-$193	﹤0.01%	747
2025 Q4	$2K	Buy	16 +10	+167%	+$1.75K	﹤0.01%	733
2025 Q3	$0	Hold	6	–	–	﹤0.01%	790
2025 Q2	$0	Buy	+6	New	+$841	﹤0.01%	759
2025 Q1	–	Sell	-5	Closed	–	–	756
2024 Q4	$0	Hold	5	–	–	﹤0.01%	752
2024 Q3	$0	Hold	5	–	–	﹤0.01%	755
2024 Q2	$0	Hold	5	–	–	﹤0.01%	735
2024 Q1	$0	Hold	5	–	–	﹤0.01%	718
2023 Q4	$0	Hold	5	–	–	﹤0.01%	719
2023 Q3	$0	Hold	5	–	–	﹤0.01%	720
2023 Q2	$0	Hold	5	–	–	﹤0.01%	767
2023 Q1	$0	Hold	5	–	–	﹤0.01%	797
2022 Q4	$0	Hold	5	–	–	﹤0.01%	767
2022 Q3	$0	Hold	5	–	–	﹤0.01%	686
2022 Q2	$1K	Buy	+5	New	+$656	﹤0.01%	445

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Coston McIsaac & Partners's AZN Position: Q2 2026 in Review

Coston McIsaac & Partners held its AstraZeneca (AZN) position steady in Q2 2026 at 15 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #758.

Coston McIsaac & Partners first reported a position in AZN in Q2 2022 and has held it in 16 quarters since. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Coston McIsaac & Partners held 15 shares of AstraZeneca worth $2K as of Q2 2026.
Coston McIsaac & Partners left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up ﹤0.01% of Coston McIsaac & Partners's portfolio in Q2 2026, its #758 holding.
Coston McIsaac & Partners first reported a position in AstraZeneca in Q2 2022 and has held it in 16 quarters since.
1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Coston McIsaac & Partners's 13F filing for Q2 2026, filed 12 Aug 2026.